Thiamphenicol induced bone marrow suppression as a therapy of myeloproliferative diseases.
Sixteen patients, suffering from myeloproliferative diseases (9 polycythaemia vera, 7 primary thrombocythaemia) and 20 control subjects were treated for 14 days with 1 g of thiamphenicol per day. The effect of 40 treatment cycles was studied. The regimen resulted in lowering the haemoglobin values by 4.8% in controls (p greater than or equal to 0.001) and patients (p greater than or equal to 0.01); the reticulocyte count dropped 43% in the patient group (p greater than or equal to 0.01) and 32% in the controls (p greater than or equal to 0.05); the thrombocyte count was decreased 42% (p greater than or equal to 0.0001) vs 29% (p greater than or equal to 0.0001) in the control group. The administration of 1 g/day of thiamphenicol for a 14 day period reduced the myelopoietic activity by 40%. The decrease of all values was statistically significant. After discontinuation of thiamphenicol therapy the haematological parameters returned to the initial values within 1-2 months. The myelodepressant activity of thiamphenicol may therefore be applied to the therapy of the myeloproliferative diseases in order to reduce the risk of spontaneous haemorrhages and thrombosis.
D001853:Bone Marrow / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D006454:Hemoglobins; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D010976:Platelet Count; D012156:Reticulocytes; D013839:Thiamphenicol / Q000009:adverse effects / Q000627:therapeutic use*
D006454:Hemoglobins; D013839:Thiamphenicol